Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Genmab acquires biotechnology company ProfoundBio in $1.8bn deal
Genmab acquires biotechnology company ProfoundBio in $1.8bn deal
Genmab has concluded the previously announced acquisition of clinical-stage biotechnology company ProfoundBio in a $1.8bn cash transaction.
FDA grants Fast Track Designation to RAG-01 in NMIBC
FDA grants Fast Track Designation to RAG-01 in NMIBC
The FDA has granted a Fast Track Designation to RAG-01, a first-in-class small activating RNA (saRNA) therapeutic under review for the treatment of patients with BCG-unresponsive non–muscle-...
Phase 2 Study Demonstrates Oral Rilzabrutinib Reduces Loss of Control Events in Patients With Asthma
Phase 2 Study Demonstrates Oral Rilzabrutinib Reduces Loss of Control Events in Patients With Asthma
According to the investigators, these findings support the investigation of rilzabrutinib in patients with asthma in a phase 3 trial program.
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditio...
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have a lot of confidence ...
FDA Withdraws Infigratinib Approval for Cholangiocarcinoma
FDA Withdraws Infigratinib Approval for Cholangiocarcinoma
The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted. The FDA approval for infigratini...
Glenmark to market BeiGene’s oncology medicines in India
Glenmark to market BeiGene’s oncology medicines in India
Glenmark Pharmaceuticals subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India. Tislelizumab and Zanubrutinib will be commer...
China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
Zai Lab and Innoviva Specialty Therapeutics have announced the approval of China’s National Medical Products Administration (NMPA) for Zai’s new drug application (NDA) submitted fo...
Newly identified biomarkers may warn of cancer 7 years before symptoms set in
Newly identified biomarkers may warn of cancer 7 years before symptoms set in
Researchers have found a link between over 1,000 blood proteins and 19 different forms of cancer.
ADHD drug shortage shows signs of letting up, but some patients still struggle
ADHD drug shortage shows signs of letting up, but some patients still struggle
Many of the ADHD (attention-deficit/hyperactivity disorder) medication shortages that have plagued the U.S. for the last two years have now been resolved, the Food and Drug Administration says...
Regeneron wins temporary restraining order preventing Eylea generic launch
Regeneron wins temporary restraining order preventing Eylea generic launch
Regeneron (NASDAQ:REGN) won a temporary restraining order that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, from launching a generic version of its blockbuster eye drug...
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial. Ionis and Biogen are halting the development of their exp...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand